Meg Rivers

This year marks my first involvement in Pharmaceutical Executive’s Emerging Pharma Leaders (EPL) Awards, and what a ride it has been. We received so many wonderful nominations, and it’s always humbling to learn about some of the intricacies of the research that’s being done as well as the accomplishments of both current leaders and up-and-coming leaders.

In this exclusive Q&A, Marie Flanagan, offering management director, IQVIA, reveals how patients are reporting adverse events in large numbers on social media.

Elizabeth (Beth) Garner, chief scientific officer for Ferring Pharmaceuticals, discusses her transition from being a physician to working in pharma, new technologies in reproductive health for men and women, as well as access limitations in fertility treatment.

Experts from Kallyope share biotech challenges they have faced and overcome as well as ways to go about securing funds in this exclusive Q&A.

Two companies team up to combat rare diseases through drug repurposing, which was heavily informed by one doctor’s experience through unconventionally treating his Castleman disease and (ultimately) saving his own life.

Judith Kulich, principal, patient health and equity lead, ZS, and Nan Gu, associate principal, patient health and equity, ZS, discuss health equity in pharma, specifically racial biases, and how the industry can address access and inequities going forward.

While KOLs have been present in healthcare marketing for some time, DOLs are now emerging.

Rebekah Martin, senior VP of reward, inclusion, and talent acquisition at AstraZeneca, discusses recruiting talent in pharma, including finding and keeping the right talent, identifying and nurturing talent (students, specifically), and diversity in the workforce.

Health disparities brought on by racial bias remain quite prevalent in areas such as drug access, use of diagnostics, and representation in clinical trials, but society-jarring events in recent years have sparked renewed efforts by industry to tackle these issues with tangible and hopeful gains.

Pharm Exec's February issue focuses on health equity.

Piper Trelstad, PhD, head of CMC, Bill & Melinda Gates Medical Research Institute, shares her experience being a woman in pharma, particularly at the C-suite level, as well as how to have more diversity in the industry.

How technology will play a big role in advancing pharma approaches in patient support.

The steps companies can take now to better protect themselves and their data.

Natalie Bickford, chief people officer at Sanofi, reveals how she approaches the employee experience, which ultimately influences employee retention, and discusses the importance of a corporate DE&I strategy in those efforts.

Pharm Exec introduces new managing editor.

One company pursues a program for a technology they believe is a potential cure for Type 1 diabetes.

In episode 125, Chris Fox, president of Novartis Gene Therapies, shares insights into her work with gene therapies, commercialization challenges, her role at Novartis, and what the team are most excited about in 2023.

Experts from Karuna Therapeutics discuss current research into schizophrenia as well as psychosis in Alzheimer's disease—including the (lack) of treatment options available for these disorders.

In episode 121, Nathalie Dompé, co-CEO of Dompé Pharmaceuticals, shares a glimpse into her journey in the pharma industry, her leadership style, the differences in working in leadership in the United States vs. Europe (Italy, specifically), and technologies in the biopharma industry.